Journal of geriatric oncology最新文献

{"title":"Response to letter to the editor: “Cardiovascular and cancer-specific mortality in older patients with advanced non-small cell lung cancer following the introduction of immuno-oncology therapies”","authors":"Yeijin Kim , Jiyeon Lee , Hae Sun Suh , Chanhyun Park","doi":"10.1016/j.jgo.2026.102928","DOIUrl":"10.1016/j.jgo.2026.102928","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 3","pages":"Article 102928"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147458144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Individualized physical activity program for older adults undergoing chemotherapy for hematologic malignancies","authors":"Baptiste Fournier ,&nbsp;Chiara Russo ,&nbsp;Aurélia Maire ,&nbsp;Romain Buono ,&nbsp;Laure Lebras ,&nbsp;Yann Guillermin ,&nbsp;Clémence Santana ,&nbsp;Philippe Rey ,&nbsp;Amine Belhabri ,&nbsp;Anne-Sophie Michallet ,&nbsp;Lucie Jauffret ,&nbsp;Emilie Pretet-Flamand ,&nbsp;Catherine Terret ,&nbsp;Mauricette Michallet ,&nbsp;Béatrice Fervers ,&nbsp;Emmanuelle Nicolas-Virelizier ,&nbsp;Olivia Pérol","doi":"10.1016/j.jgo.2026.102901","DOIUrl":"10.1016/j.jgo.2026.102901","url":null,"abstract":"<div><h3>Introduction</h3><div>Older adults with hematologic malignancies are at high risk of treatment-related functional decline. Although physical activity (PA) may mitigate these effects, evidence in older adults with acute myeloid leukemia (AML) and non-Hodgkin lymphoma (NHL) remains limited. We evaluated the feasibility and exploratory effects of a 6-month individualized PA program delivered during and after chemotherapy in this population.</div></div><div><h3>Material and methods</h3><div>The OncoGeriatric and Individualized Physical Activity (OCAPI) study is a single-arm, prospective feasibility study evaluating a 6-month individualized PA program in AML/NHL patients ≥65 years receiving chemotherapy <em>±</em> immunotherapy. The PA program included supervised and unsupervised sessions, an activity tracker, and motivational phone calls. The primary outcome was progam adherence. Secondary outcomes were feasibility metrics (recruitment, retention, adherence, safety, and patient satisfaction) assessed throughout the study, and exploratory effectiveness measures (physical condition, PA behavior, and patient-reported and geriatric outcomes) evaluated at baseline, three, and six months.</div></div><div><h3>Results</h3><div>Forty-two participants were enrolled. Rates of recruitment and retention were 59% and 88%, respectively. Adherence was 66% for supervised sessions, and &lt; 5% for unsupervised ones. Activity trackers were worn 63% of the prescribed time and 75% of scheduled calls were completed. No exercise-related adverse events occurred. Patient satisfaction was high (96%). Perceived usefulness was 91% for supervised sessions, 54% for unsupervised sessions, 84% for the activity tracker, and 86% for motivational calls. At three months, in the overall cohort, handgrip strength showed a decline and balance an improvement, but there were no changes in other performance, patient-reported, or geriatric outcomes. Changes in limb strength and walking endurance may varied by diagnosis, with NHL patients tending to improve, and AML ones tending to decline. At six months, among all participants, walking endurance improved significantly and clinically (+53 m in the 6-Minute Walk Test, <em>p</em> = 0.01), while left-hand grip strength declined. Nutritional status and quality of life also showed improvement, with no notable changes in other outcomes.</div></div><div><h3>Discussion</h3><div>The individualized PA program was feasible and safe for older patients with AML/NHL during chemotherapy. Exploratory effectivenness findings suggest that patients improved walking endurance and quality of life and diagnosis-specific functional trajectories. Larger multicenter trials are needed to confirm these preliminary observations.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 3","pages":"Article 102901"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146154195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Geriatric oncology in 2040: Exploring potential realities and challenges. A diverse perspective","authors":"Raymond Gardner ,&nbsp;Luciola Pontes Leite de Barros ,&nbsp;Kwok Leung Cheung ,&nbsp;William Dale ,&nbsp;Lore Decoster ,&nbsp;Barbara Ewals ,&nbsp;Cindy Kenis ,&nbsp;Martine Puts ,&nbsp;Christopher Steer ,&nbsp;Hans Wildiers ,&nbsp;Grant Williams ,&nbsp;Nicolò Matteo Luca Battisti","doi":"10.1016/j.jgo.2026.102907","DOIUrl":"10.1016/j.jgo.2026.102907","url":null,"abstract":"<div><div>The average global life expectancy is predicted to increase to approximately 80 years by 2040 [<span><span>1</span></span>]. Cancer is an ageing-related disease, and its prevalence will also increase with this ageing of the population [<span><span>2</span></span>]. This rise in older adults living with cancer will demand innovation in service delivery, multidisciplinary collaboration, and a renewed focus on compassionate, patient-centred care. We are therefore compelled to rethink how we approach cancer diagnosis, treatment, and survivorship. This white paper explores the potential realities and challenges through a multidimensional lens, addressing the intersection of demographic shifts, rapid technological advancements, and the evolving needs of older adults living with cancer. Key areas examined include the integration of precision medicine and digital health tools, the adaptation of healthcare delivery models, and the implications for workforce training and resource allocation.</div><div>The discussion highlights disparities in care, the importance of personalised interventions, and strategies to enhance quality of life for older adults with cancer. By anticipating these developments, the paper offers critical insights for policymakers (who set the rules and goals and allocate funding), health system leaders (who manage the day-to-day operations), clinicians and allied health professionals (who are patient-facing), and patients and caregivers, aiming to promote equity, innovation, quality and resilience in the care of older adults with cancer as we approach the next decade.</div><div>The paper seeks to consolidate and clarify the diverse issues and opportunities that will emerge as the global population ages and the burden of cancer among older adults rises. With average life expectancy predicted to approach 80 years by 2040, and cancer recognised as a disease closely linked to ageing [<span><span>3</span></span>], the paper brings together expert perspectives to provide a sector-wide synthesis of the impending challenges. Its purpose is not to offer a conventional systematic review, but rather to serve as a strategic resource for policymakers, health system leaders, clinicians, allied health professionals, patients, and caregivers, informing the response to demographic shifts, technological advances and evolving patient needs. By consolidating insights on disparities in care, the necessity for personalised interventions, and strategies to enhance quality of life, the paper aims to inform and inspire innovation, equity and resilience in geriatric oncology as we approach the next decade.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 3","pages":"Article 102907"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147317419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor: Cardiovascular and cancer-specific mortality in older patients with advanced non-small cell lung cancer following the introduction of immuno-oncology therapies","authors":"Sari Luthfiyah ,&nbsp;Ach. Arfan Adinata ,&nbsp;Joylyn L. Mejilla ,&nbsp;Mohammed Ismath","doi":"10.1016/j.jgo.2026.102929","DOIUrl":"10.1016/j.jgo.2026.102929","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 3","pages":"Article 102929"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147365328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Getting the right measure: Gait speed assessment and outcomes in older patients with cancer","authors":"Evelien R.A. Spruijt ,&nbsp;Ajay T. Bakas ,&nbsp;Aniel Sewnaik ,&nbsp;Christian Oudshoorn ,&nbsp;Francesco Mattace-Raso ,&nbsp;Rob J. Baatenburg de Jong ,&nbsp;Harmke A. Polinder-Bos","doi":"10.1016/j.jgo.2026.102908","DOIUrl":"10.1016/j.jgo.2026.102908","url":null,"abstract":"<div><h3>Introduction</h3><div>Gait speed (GS) reflects an individual's physical capacity and is often used to assess the level of fitness in older individuals with cancer. Importantly, GS can be measured in various ways. This study examined the association between several GS measurements and one-year mortality in older patients with head and neck cancer.</div></div><div><h3>Materials and methods</h3><div>This prospective cohort study included 227 patients. GS was measured at usual and fast pace using a 5-m walkway. GS reserve (fast-usual GS) and GS ratio (fast/usual GS) were calculated. GS measurements were analyzed both as continuous and categorical variables. For the categorical analyses, two categorical GS variables were created: ‘1 m/s’ and ‘25th percentile.’ Each variable included three categories: for ‘1 m/s’: usual and fast GS &lt;1 m/s, usual GS &lt;1 m/s and fast GS ≥1 m/s, and usual and fast GS ≥1 m/s; for ‘25th-percentile’: usual and fast GS &lt; p25, usual GS &lt; p25 and fast GS ≥ p25, and usual and fast GS ≥ p25. Cox regression survival analyses were performed.</div></div><div><h3>Results</h3><div>Median age was 76 [IQR 72–80] years, 71% were men and 51 patients died within one year. Mean usual and fast GS were 1.08 ± 0.27 and 1.41 ± 0.39 m/s, respectively. A higher usual (HR 0.23, 95%CI 0.07–0.76) or fast GS (HR 0.36, 95%CI 0.14–0.91) were associated with lower mortality. Patients with usual and fast GS &lt;1 m/s (HR 2.66, 95%CI 1.29–5.50) had a higher mortality risk compared to patients with usual and fast GS &gt;1 m/s. The association of 25th percentile group with mortality attenuated after adjustment for treatment (HR 2.07, 95%CI 0.91–4.73). Neither GS reserve nor GS ratio were associated with mortality.</div></div><div><h3>Discussion</h3><div>Lower usual and fast gait speeds are associated with higher one-year mortality in patients with head and neck cancer. A simple guideline is that patients with usual and fast GS &lt;1 m/s or &lt; p25 have a twofold higher risk of dying within one year compared to patients who walk faster.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 3","pages":"Article 102908"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147306745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What nutritional interventions can effectively treat sarcopenia in older adults with cancer? A systematic review","authors":"Megan Pattwell ,&nbsp;Michelle Gibbs ,&nbsp;Colm Mac Eochagáin ,&nbsp;Emma Crewe ,&nbsp;Anne Barrell ,&nbsp;Erin Stella Sullivan ,&nbsp;Hannah Furness ,&nbsp;Ione de Brito-Ashurst ,&nbsp;Susanne Cruickshank ,&nbsp;Nicolò Matteo Luca Battisti","doi":"10.1016/j.jgo.2026.102850","DOIUrl":"10.1016/j.jgo.2026.102850","url":null,"abstract":"<div><h3>Introduction</h3><div>Cancer primarily affects older adults, with a significant proportion also experiencing sarcopenia which is associated with poor clinical outcomes. In older adults with cancer, sarcopenia is not only age-related but also exacerbated by disease processes, inflammation, and the catabolic effects of treatments such as chemotherapy and radiotherapy. Its presence is linked to increased treatment toxicity, longer hospitalisations, reduced physical function, and poorer survival rates. However, diagnosing sarcopenia remains challenging due to inconsistent criteria and limited access to diagnostic tools. Emerging evidence suggests that nutritional interventions may help prevent or reverse sarcopenia. This review aims to evaluate the effectiveness of nutritional interventions in managing sarcopenia in older adults with cancer.</div></div><div><h3>Materials and methods</h3><div>A systematic review was conducted using the PICO framework, targeting studies involving patients aged 65 and older with cancer and confirmed or likely sarcopenia. A total of 1439 studies were retrieved from databases and screened using Rayyan. Data extraction focused on outcomes related to body composition, physical performance, and nutritional intake. Risk of bias was assessed using RoB2, ROBINS-I, and ROBINS-E tools. Due to heterogeneity in study designs and outcome measures, a narrative synthesis was performed using SWiM guidelines. Studies were grouped by design and intervention type, and the GRADE approach was applied to assess evidence certainty.</div></div><div><h3>Results</h3><div>Nine studies (2016–2024) met the inclusion criteria. Interventions included dietary supplements, nutritional counselling, enteral feeding, and multimodal strategies. Most studies showed improvements in sarcopenia-related outcomes. Protein supplementation notably improved lean body mass and skeletal muscle index in some randomised control trials (RCTs). Observational studies found associations between certain dietary patterns—such as high fish and fat intake—and reduced sarcopenia risk.</div></div><div><h3>Discussion</h3><div>Nutritional interventions show promise in managing sarcopenia among older adults with cancer. However, further large-scale, standardised research is needed. Meanwhile, promoting good nutrition and physical activity remains essential.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102850"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146018535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a new model for prediction of relevant treatment related adverse events in older individuals with gastrointestinal cancers","authors":"Vallish Shenoy ,&nbsp;Sadhana Kannan ,&nbsp;Vanita Noronha ,&nbsp;Kumar Prabhash ,&nbsp;Vikas Ostwal ,&nbsp;Prabhat Bhargava ,&nbsp;Anupa Pillai ,&nbsp;K. Shamseeya ,&nbsp;Ankush Shetake ,&nbsp;Ratan Dhekale ,&nbsp;Ankita Chitre ,&nbsp;Vikram Gota ,&nbsp;Sarika Mahajan ,&nbsp;Anuradha Daptardar ,&nbsp;Lekhika Sonkusare ,&nbsp;Jayita Deodhar ,&nbsp;Nabila Ansari ,&nbsp;Manjusha Vagal ,&nbsp;Purabi Mahajan ,&nbsp;Manjunath Nookala ,&nbsp;Anant Ramaswamy","doi":"10.1016/j.jgo.2025.102817","DOIUrl":"10.1016/j.jgo.2025.102817","url":null,"abstract":"<div><h3>Introduction</h3><div>Limited tools exist to specifically predict the risk of chemotherapy toxicity and related events in older individuals with gastrointestinal (GI) cancers.</div></div><div><h3>Materials and Methods</h3><div>We evaluated patients aged ≥60 years with GI cancers who underwent a comprehensive geriatric assessment comprising demographic, cancer variables, and geriatric domains (function, comorbidities, nutritional status, medications, cognition, psychological status, and social support). A Cancer and Aging Research Group (CARG) score was calculated in all patients. The occurrence of grade 3 to 5 adverse events, emergent hospitalizations, and sudden death without identifiable adverse events were defined as treatment related adverse events (TRAE) to form the new predictive model. Based on initial univariate analysis of factors predicting for TRAE and then multivariate analysis, a nomogram was developed to predict the probability TRAEs. The total score derived from the nomogram was categorized into low, moderate, and high-risk groups based on a recursive partitioning algorithm.</div></div><div><h3>Results</h3><div>In total, 701 patients with a median age of 67 years (range, 60 to 88 years) with predominantly stage IV cancers (58 %) were analysed. The distribution of GI cancers was gastric and esophageal cancers (<em>n</em> = 349, 50 %), hepatobiliary and pancreatic cancers (<em>n</em> = 241, 34 %), and colorectal cancers (<em>n</em> = 84, 12 %). TRAE occurred in 53 % of the patients. A predictive model for TRAE was developed using the Mobility-Tiredness (Mob-T) Scale, hearing, cancer stage, site of primary, and chemotherapy dosing (standard or reduced). A predictive score in which the median risk score was 22 (range, 0 to 40) and risk stratification identified older adults at low risk (0 to 13 points; 17 %), intermediate risk (14 to 21 points; 40 %), or high risk (&gt;22 points; 71 %) of chemotherapy toxicity (<em>P</em> &lt; 0.001). The new model outperformed the CARG score based on ROC analysis (0.75 vs 0.59, <em>p</em> &lt; 0.001).</div></div><div><h3>Discussion</h3><div>A new and simpler risk score predicts for chemotherapy related adverse events in older patients with GI cancers and seems to be more accurate than the CARG score. The score requires validation in prospective studies.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102817"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145692903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dizziness and impaired postural balance in older patients receiving chemotherapy treatment: A systematic review and meta-analysis","authors":"Katrine Storm Piper ,&nbsp;Martine Puts ,&nbsp;Cecilia Lund ,&nbsp;Jesper Ryg ,&nbsp;Charlotte Suetta ,&nbsp;Hanne Elkjær Andersen ,&nbsp;Jakob Vasehus Schou ,&nbsp;Allan Madsen ,&nbsp;Jan Christensen","doi":"10.1016/j.jgo.2025.102816","DOIUrl":"10.1016/j.jgo.2025.102816","url":null,"abstract":"<div><h3>Introduction</h3><div>Dizziness and balance impairments are underexplored symptoms in older adults with cancer. Age-related factors, comorbidities, and chemotherapy may contribute to its prevalence and severity, potentially affecting quality of life, increasing fall risk, and delaying treatment. Data on the incidence and prevalence of these symptoms are limited. This systematic review aimed to summarize the evidence and estimate the incidence and prevalence of dizziness or vertigo and impaired postural balance in patients with cancer ≥65 years receiving chemotherapy.</div></div><div><h3>Materials and Methods</h3><div>We searched PubMed, EMBASE, CENTRAL, and CINAHL in May 2025 without date or language restrictions. Cross sectional studies, cohort studies, randomized controlled trials, and mixed method studies investigating incidence and/or prevalence of dizziness or vertigo and impaired postural balance were included. Random-effects meta-analysis, employing the inverse-variance method, was applied. Certainty of evidence was rated by the Grading of Recommendations Assessment and Evaluation (GRADE) approach.</div></div><div><h3>Results</h3><div>From 15,614 title/abstracts screened, 14 studies (1259 participants) were included. Incidence could not be evaluated. Studies reporting prevalence across multiple chemotherapy regimens contributed separate estimates for each regimen. Meta-analysis included 25 prevalence estimates for dizziness and three for impaired postural balance. The pooled prevalence of dizziness was 15 % (95 % CI:10 %–22 %). Assessor-reported prevalence using the Common Terminology Criteria for Adverse Events (CTCAE) was 11 % (95 % CI: 8 %–16 %), while patient-reported prevalence rate using the European Organisation for Research and Treatment of Cancer Chemotherapy Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20), or a self-constructed questionnaire was 35 % (95 % CI: 20 %–53 %). Most studies demonstrated a high risk of bias, and certainty of evidence was very low due to unstructured assessor-reported measurement methods. Impaired postural balance prevalence from one study was 48 % (95 % CI: 39 %–57 %) with low certainty of evidence. Prevalence of dizziness and impaired postural balance did not differ significantly across chemotherapy regimens.</div></div><div><h3>Discussion</h3><div>Prevalence of dizziness and impaired postural balance in older patients receiving chemotherapy varied substantially depending on the measurement method, with higher rates in patient-reported outcomes. Certainty of evidence was low primarily due to limitations in outcome measures. Future studies should incorporate patient-reported outcome measures and a systematic objective baseline assessment for a comprehensive evaluation of these symptoms.</div><div>Trial registration: PROSPERO CRD42024585974.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102816"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145692902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integration of geriatric assessment and management recommendations for older adults with non-small cell lung cancer (NSCLC) receiving chemotherapy/radiation treatment (GAM-CRT): A preliminary analysis","authors":"C. Presley ,&nbsp;H. Antao ,&nbsp;M. Grogan ,&nbsp;V. Katheria ,&nbsp;C. Sun ,&nbsp;H. Kim ,&nbsp;L. Mitchell ,&nbsp;J. Loubes ,&nbsp;B. Wind ,&nbsp;A. Pannella ,&nbsp;V. Branch ,&nbsp;L. Lupercio ,&nbsp;D. Spakowicz ,&nbsp;C. Burd ,&nbsp;M. Wong ,&nbsp;A. Amini ,&nbsp;W. Dale ,&nbsp;S. Mohile","doi":"10.1016/j.jgo.2026.102888","DOIUrl":"10.1016/j.jgo.2026.102888","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102888"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147448612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes and toxicity of immune checkpoint inhibitors (ICIs) in advanced bladder cancer: A real-world study in geriatric Asian population","authors":"H.S. Tan ,&nbsp;J.X.J. Tan ,&nbsp;X.H. Tan ,&nbsp;Q.S. Ng ,&nbsp;J. Chan ,&nbsp;W.C. Tan ,&nbsp;A. Roy Chowdhury ,&nbsp;R. Kanesvaran","doi":"10.1016/j.jgo.2026.102881","DOIUrl":"10.1016/j.jgo.2026.102881","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"17 2","pages":"Article 102881"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147449059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}